Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
| Autor: | Joong Yeol Park, Min Jung Lee, Chang Hee Jung, Eun Seok Kang, Eun Yeong Choe, Hye Jin Wang, Jaehyun Bae, Yu Seun Kim, Myoung Soo Kim |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Dipeptidyl-peptidase IV inhibitors
animal structures Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Linagliptin 030204 cardiovascular system & hematology Pharmacology lcsh:Diseases of the endocrine glands. Clinical endocrinology Sitagliptin Phosphate Kidney transplantation 03 medical and health sciences 0302 clinical medicine Endocrinology Diabetes mellitus medicine Vildagliptin Dipeptidyl peptidase-4 lcsh:RC648-665 business.industry medicine.disease Renal transplant Sitagliptin Clinical Study Cyclosporine Sitagliptin phosphate Original Article business medicine.drug |
| Zdroj: | Endocrinology and Metabolism, Vol 31, Iss 1, Pp 161-167 (2016) Endocrinology and Metabolism |
| ISSN: | 2093-5978 |
| Popis: | Background The use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been fully investigated. We compared the glucose-lowering efficacies of DPP 4 inhibitors and evaluate their effects on the blood levels of cyclosporine in renal transplant recipients with diabetes. Methods Sixty-five renal allograft recipients who received treatment with DPP-4 inhibitors (vildagliptin, sitagliptin, or linagliptin) following kidney transplant were enrolled. The glucose-lowering efficacies of the DPP-4 inhibitors were compared according to the changes in the hemoglobin A1c (HbA1c) levels after 3 months of treatment. Changes in the trough levels of the cyclosporine were also assessed 2 months after treatment with each DPP-4 inhibitor. Results HbA1c significantly decreased in the linagliptin group in comparison with other DPP-4 inhibitors (vildagliptin –0.38%±1.03%, sitagliptin –0.53%±0.95%, and linagliptin –1.40±1.34; P=0.016). Cyclosporine trough levels were significantly increased in the sitagliptin group compared with vildagliptin group (30.62±81.70 ng/mL vs. –24.22±53.54 ng/mL, P=0.036). Cyclosporine trough levels were minimally changed in patients with linagliptin. Conclusion Linagliptin demonstrates superior glucose-lowering efficacy and minimal effect on cyclosporine trough levels in comparison with other DPP-4 inhibitors in kidney transplant patients with diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|